This HTML5 document contains 75 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n8http://linked.opendata.cz/resource/drugbank/drug/DB00800/identifier/iuphar/
n11http://www.rxlist.com/cgi/generic3/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00800/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00800/identifier/guide-to-pharmacology/
foafhttp://xmlns.com/foaf/0.1/
n18http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/mesh/concept/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00800/identifier/national-drug-code-directory/
n21http://linked.opendata.cz/resource/drugbank/dosage/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00800/identifier/chemspider/
n20http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB00800/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00800/identifier/wikipedia/
n29http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00800/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n24http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n22http://linked.opendata.cz/ontology/mesh/
n13http://linked.opendata.cz/ontology/drugbank/
n14http://linked.opendata.cz/resource/drugbank/property/
n4http://linked.opendata.cz/resource/drugbank/drug/DB00800/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n5http://linked.opendata.cz/resource/drugbank/drug/DB00800/identifier/pubchem-substance/
n27http://linked.opendata.cz/ontology/sukl/drug/
n28http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00800/identifier/kegg-drug/

Statements

Subject Item
n2:DB00800
rdf:type
n13:Drug
n13:description
A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation. [PubChem]
n13:dosage
n21:271B3EAC-363D-11E5-9242-09173F13E4C5
n13:group
approved
n13:halfLife
The elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.
n13:indication
For the in-hospital, short-term (up to 48 hours) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function.
n13:manufacturer
n18:271B3EA9-363D-11E5-9242-09173F13E4C5 n18:271B3EA7-363D-11E5-9242-09173F13E4C5 n18:271B3EA8-363D-11E5-9242-09173F13E4C5 n18:271B3EA5-363D-11E5-9242-09173F13E4C5 n18:271B3EA6-363D-11E5-9242-09173F13E4C5
owl:sameAs
n20:DB00800 n29:DB00800
dcterms:title
Fenoldopam
adms:identifier
n4:3341 n5:46504963 n6:55390-071-01 n8:939 n9:D00613 n12:DB00800 n15:939 n16:5002 n17:3224 n25:Fenoldopam n26:PA164784034
n13:mechanismOfAction
Fenoldopam is a rapid-acting vasodilator. It is an agonist for D<sub>1</sub>-like dopamine receptors and binds with moderate affinity to &alpha;<sub>2</sub>-adrenoceptors. It has no significant affinity for D<sub>2</sub>-like receptors, &alpha;<sub>1</sub> and &beta;-adrenoceptors, 5<sub>HT1</sub> and 5<sub>HT2</sub> receptors, or muscarinic receptors. Fenoldopam is a racemic mixture with the R-isomer responsible for the biological activity. The R-isomer has approximately 250-fold higher affinity for D<sub>1</sub>-like receptors than does the S-isomer. In non-clinical studies, fenoldopam had no agonist effect on presynaptic D<sub>2</sub>-like dopamine receptors, or &alpha; or &beta; -adrenoceptors, nor did it affect angiotensin-converting enzyme activity. Fenoldopam may increase norepinephrine plasma concentration.
n13:packager
n18:271B3EA3-363D-11E5-9242-09173F13E4C5 n18:271B3EA4-363D-11E5-9242-09173F13E4C5 n18:271B3EA1-363D-11E5-9242-09173F13E4C5 n18:271B3EA2-363D-11E5-9242-09173F13E4C5 n18:271B3E9F-363D-11E5-9242-09173F13E4C5 n18:271B3EA0-363D-11E5-9242-09173F13E4C5
n13:routeOfElimination
Radiolabeled studies show that about 90% of infused fenoldopam is eliminated in urine, 10% in feces. Elimination is largely by conjugation, without participation of cytochrome P-450 enzymes. Only 4% of the administered dose is excreted unchanged.
n13:synonym
Fenoldopamum Fenoldopam Fénoldopam
n13:toxicity
The most likely reaction of overdose would be excessive hypotension which should be treated with drug discontinuation and appropriate supportive measures.
n13:salt
n13:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Fenoldopam.htm
n22:hasConcept
n23:M0028173
foaf:page
n11:fenoldopam.htm
n13:IUPAC-Name
n14:271B3EB1-363D-11E5-9242-09173F13E4C5
n13:InChI
n14:271B3EB7-363D-11E5-9242-09173F13E4C5
n13:Molecular-Formula
n14:271B3EB6-363D-11E5-9242-09173F13E4C5
n13:Molecular-Weight
n14:271B3EB3-363D-11E5-9242-09173F13E4C5
n13:Monoisotopic-Weight
n14:271B3EB4-363D-11E5-9242-09173F13E4C5
n13:SMILES
n14:271B3EB5-363D-11E5-9242-09173F13E4C5
n13:Water-Solubility
n14:271B3EC7-363D-11E5-9242-09173F13E4C5 n14:271B3EAF-363D-11E5-9242-09173F13E4C5
n13:logP
n14:271B3EC8-363D-11E5-9242-09173F13E4C5 n14:271B3EAD-363D-11E5-9242-09173F13E4C5 n14:271B3EB0-363D-11E5-9242-09173F13E4C5
n13:logS
n14:271B3EAE-363D-11E5-9242-09173F13E4C5
n27:hasATCCode
n28:C01CA19
n13:H-Bond-Acceptor-Count
n14:271B3EBD-363D-11E5-9242-09173F13E4C5
n13:H-Bond-Donor-Count
n14:271B3EBE-363D-11E5-9242-09173F13E4C5
n13:InChIKey
n14:271B3EB8-363D-11E5-9242-09173F13E4C5
n13:Polar-Surface-Area--PSA-
n14:271B3EB9-363D-11E5-9242-09173F13E4C5
n13:Polarizability
n14:271B3EBB-363D-11E5-9242-09173F13E4C5
n13:Refractivity
n14:271B3EBA-363D-11E5-9242-09173F13E4C5
n13:Rotatable-Bond-Count
n14:271B3EBC-363D-11E5-9242-09173F13E4C5
n13:affectedOrganism
Humans and other mammals
n13:casRegistryNumber
67227-57-0
n13:category
n13:containedIn
n24:271B3EAB-363D-11E5-9242-09173F13E4C5 n24:271B3EAA-363D-11E5-9242-09173F13E4C5
n13:Bioavailability
n14:271B3EC3-363D-11E5-9242-09173F13E4C5
n13:Ghose-Filter
n14:271B3EC5-363D-11E5-9242-09173F13E4C5
n13:MDDR-Like-Rule
n14:271B3EC6-363D-11E5-9242-09173F13E4C5
n13:Number-of-Rings
n14:271B3EC2-363D-11E5-9242-09173F13E4C5
n13:Physiological-Charge
n14:271B3EC1-363D-11E5-9242-09173F13E4C5
n13:Rule-of-Five
n14:271B3EC4-363D-11E5-9242-09173F13E4C5
n13:Traditional-IUPAC-Name
n14:271B3EB2-363D-11E5-9242-09173F13E4C5
n13:pKa--strongest-acidic-
n14:271B3EBF-363D-11E5-9242-09173F13E4C5
n13:pKa--strongest-basic-
n14:271B3EC0-363D-11E5-9242-09173F13E4C5